Credit Suisse Reaffirms Underperform Rating on Amlin (AML)
Amlin (LON: AML)‘s stock had its “underperform” rating restated by analysts at Credit Suisse in a research report issued to clients and investors on Tuesday. They currently have a $5.98 (372 GBX) price target on the stock.
Several other analysts have also recently commented on the stock. Analysts at Barclays Capital reiterated an “overweight” rating on shares of Amlin in a research note to investors on Monday. They now have a $7.90 price target on the stock. Separately, analysts at Nomura reiterated a “neutral” rating on shares of Amlin in a research note to investors on Thursday, January 3rd. They now have a $6.85 price target on the stock. Finally, analysts at JPMorgan Chase reiterated an “underweight” rating on shares of Amlin in a research note to investors on Thursday, December 20th. They now have a $5.85 price target on the stock.
Amlin opened at 392.30 on Tuesday. Amlin has a 1-year low of GBX 307.80 and a 1-year high of GBX 408.30. The stock’s 50-day moving average is currently GBX 395.2. The company’s market cap is £1.941 billion.
Amlin plc is engaged in non-life insurance and reinsurance underwriting in the Lloyd’s market, Bermuda and Continental Europe.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.